SEARCH

SEARCH BY CITATION

References

  • 1
    Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Am Med Assoc 2005;293:71522.
  • 2
    Sousou T, Khorana AA. New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol 2009;29:31620.
  • 3
    Di Nisio M, Ferrante N, De Tursi M, et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2010;104:104954.
  • 4
    Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006;118:55568.
  • 5
    Haim N, Lanir N, Hoffman R, et al. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 2001;110:916.
  • 6
    Green D, Maliekel K, Sushko E, et al. Activated-protein-C resistance in cancer patients. Haemostasis 1997;27:1128.
  • 7
    Soyer N, Kececi B, Eroglu Z, et al. Acquired activated protein C resistance in sarcoma patients. Blood Coagul Fibrinolysis 2012;23:42833.
  • 8
    Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 1989;63:13037.
  • 9
    Mukherjee SD, Swystun LL, Mackman N, et al. Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients. Pathophysiol Haemost Thromb 2010;37:8897.
  • 10
    Elice F, Fink L, Tricot G, et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006;134:399405.
  • 11
    Erman M, Abali H, Oran B, et al. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann Oncol 2004;15:16226.
  • 12
    Ferroni P, Riondino S, Portarena I, et al. Association between increased tumor necrosis factor-alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer. Int J Colorectal Dis 2012;27:15617.
  • 13
    Negaard HF, Iversen PO, Østenstad B, et al. Increased acquired activated protein C resistance in unselected patients with hematological malignancies. J Thromb Haemost 2008;6:14827.
  • 14
    Ferroni P, Martini F, Portarena I, et al. Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients–a pilot study. Support Cancer Care 2012;20:271320.
  • 15
    Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:49027.
  • 16
    Ferroni P, Martini F, Portarena I, et al. An APC-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients. Thromb Haemost 2011;105:9312.
  • 17
    Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011;29:2099103.
  • 18
    Mandalà M, Barni S, Prins M, et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 2010;21:8716.
  • 19
    Ferroni P, Della-Morte D, Palmirotta R, et al. Platinum based compounds and risk for cardiovascular toxicity in the elderly: role of the antioxidants in chemoprevention. Rejuvenation Res 2011;14:293308.
  • 20
    Daher IN, Yeh ET. Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med 2008;5:797805.
  • 21
    Barni S, Labianca R, Agnelli G, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 2011;9:17985.
  • 22
    Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 2012;7:2912.
  • 23
    Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with Cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011;29:346673.
  • 24
    Roselli M, Mineo TC, Basili S, et al. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer. Relationship with coagulation and platelet activation markers. Thromb Haemost 2003;89:17784.
  • 25
    Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009;27:491926.